疏肝解郁胶囊联合艾司西酞普兰治疗躯体疾病患者的临床研究
|
摘要
目的探讨疏肝解郁胶囊联合艾司西酞普兰治疗躯体疾病的临床效果及安全性。方法选择2015年1月～2017年12月重庆市精神卫生中心收治的87例躯体疾病患者,按随机数字表法分为对照组和治疗组,其中对照组43例,治疗组44例。对照组予艾司西酞普兰治疗,治疗组给予疏肝解郁胶囊联合艾司西酞普兰治疗,两组均连续治疗3个月。评价并比较两组治疗前后的抑郁自评量表(SDS)、焦虑自评量表(SAS)及90项症状自评量表(SCL-90)评分。比较两组治疗过程中的治疗措施依从率、服药依从率、检查依从率及康复锻炼依从率。比较两组患者治疗过程中不良反应的发生情况。结果治疗后,两组SDS、SAS、SCL-90评分均低于本组治疗前,且治疗组SDS、SAS及SCL-90评分低于对照组(P <0.05)。治疗组的治疗措施依从率、服药依从率、检查依从率及康复锻炼依从率均明显高于对照组(P <0.05)。治疗组治疗过程中的不良反应发生率明显低于对照组(P <0.05)。结论疏肝解郁胶囊联合艾司西酞普兰能够明显改善躯体疾病患者的焦虑抑郁状态,提高治疗依从性,且安全性较好,值得在临床上推广应用。
Objective To explore clinical efficacy and safety of Shugan Jieyu Capsules combined with Escitalopram in treatment for patients with somatic diseases. Methods A total of 87 patients with somatic diseases in Chongqing Mental Health Center from January 2015 to December 2017 were selected and they were divided into control group and treatment group by the random number table method, with 43 cases in the control group and 44 cases in the treatment group. Control group was treated with Escitalopram, while the treatment group was treated with Shugan Jieyu Capsules combined with Escitalopram. The two groups were treated for 3 months continously. The self-rating depression scale(SDS), self-rating anxiety scale(SAS) scores and symptom check-list 90(SCL-90) scores of the two groups before and after treatment were evaluated and compared. The treatment compliance rate, medication adherence rate, check compliance rate, rehabilitation exercise adherence rate were compared between the two groups. Adverse reaction rate of the two groups during the treatment were compared. Results After treatment, the SDS, SAS and SCL-90 scores of the two groups were significantly lower than those before treatment, and those of the treatment group were significantly lower than the control group(P < 0.05). Treatment compliance rate, medication adherence rate, check compliance rate and rehabilitation exercise adherence rate of the treatment group were significantly higher than the control group(P < 0.05).The adverse reaction rate of the treatment group during treatment was significantly lower than that of the control group(P < 0.05). Conclusion Shugan Jieyu Capsules combined with Escitalopram can improve the symptoms of anxiety and depression in patients with somatic diseases, and improve the treatment compliance, which has good security and is worthy clinical promotion.
Objective To explore clinical efficacy and safety of Shugan Jieyu Capsules combined with Escitalopram in treatment for patients with somatic diseases. Methods A total of 87 patients with somatic diseases in Chongqing Mental Health Center from January 2015 to December 2017 were selected and they were divided into control group and treatment group by the random number table method, with 43 cases in the control group and 44 cases in the treatment group. Control group was treated with Escitalopram, while the treatment group was treated with Shugan Jieyu Capsules combined with Escitalopram. The two groups were treated for 3 months continously. The self-rating depression scale(SDS), self-rating anxiety scale(SAS) scores and symptom check-list 90(SCL-90) scores of the two groups before and after treatment were evaluated and compared. The treatment compliance rate, medication adherence rate, check compliance rate, rehabilitation exercise adherence rate were compared between the two groups. Adverse reaction rate of the two groups during the treatment were compared. Results After treatment, the SDS, SAS and SCL-90 scores of the two groups were significantly lower than those before treatment, and those of the treatment group were significantly lower than the control group(P < 0.05). Treatment compliance rate, medication adherence rate, check compliance rate and rehabilitation exercise adherence rate of the treatment group were significantly higher than the control group(P < 0.05).The adverse reaction rate of the treatment group during treatment was significantly lower than that of the control group(P < 0.05). Conclusion Shugan Jieyu Capsules combined with Escitalopram can improve the symptoms of anxiety and depression in patients with somatic diseases, and improve the treatment compliance, which has good security and is worthy clinical promotion.
引文
[1]陈伟,刘秀芝.老年慢性躯体疾病与抑郁心理障碍关系及护理对策[J].中国民间疗法,2018,26(2):99-100.
[2]朴轶峰,李镔,李论,等.住院精神障碍患者合并躯体疾病的调查分析[J].中国当代医药,2017,24(26):151-153.
[3]邵海燕,杨洪娟.精神疾病患者合并躯体疾病的诊治策略[J].临床医药文献电子杂志,2017,4(46):8948-8949.
[4]李文科,钟世洪.艾司西酞普兰治疗伴焦虑症状的抑郁症的研究[J].中国社区医师,2018,34(2):11-13.
[5]李丽静.艾司西酞普兰治疗抑郁症的有效性与安全性分析[J].北方药学,2018,15(1):152-153.
[6]王凯丽,闫西鹏,赵颖颖,等.中医治疗焦虑抑郁症简况[J]实用中医内科杂志,2016,30(9):113-116.
[7]郑晓东,李俊,易飞.疏肝解郁胶囊治疗脑卒中后抑郁患者疗效及日常生活活动能力研究[J].中风与神经疾病杂志,2017,34(5):446-448.
[8]中华医学会精神科分会.CCMD-3中国精神障碍分类与诊断标准[M].济南:山东科学技术出版社,2001:118.
[9]中华医学会精神病学分会.中国精神疾病防治指南[M].北京:北京大学医学出版社,2010:26-30.
[10]吴江,贾建平.神经病学[M].3版.北京:人民卫生出版社,2015:521-523.
[11]汪向东.心理卫生评定量表手册(增订版)[M].北京:中国心理卫生杂志社,1999:223-226.
[12]王洪娟,吴忠海.老年抑郁症与共患躯体疾病、社会支持的关系[J].齐齐哈尔医学院学报,2017,38(5):513-514
[13]马春锋.抑郁发作和复发性抑郁障碍合并躯体疾病的临床分析[J].临床医药文献电子杂志,2017,4(90):17 642-17 644.
[14]张俊,林秀洁,黄礼传.艾司西酞普兰与舒肝解郁胶囊治疗脑卒中后抑郁症对照观察[J].海峡药学,2017,29(5):160-162.
[15]徐彩霞,邓文,李美银,等.艾司西酞普兰与氟西汀治疗老年抑郁症的疗效与安全性对比观察[J].临床合理用药杂志,2012,5(12):39-40.
[16]李开凤.中西医结合治疗焦虑抑郁症疗效观察[J].深圳中西医结合杂志,2015,25(21):33-34.
[17]王学红,杨业,官聪,等.疏肝解郁胶囊联合艾司西酞普兰对老年躯体疾病伴发焦虑抑郁患者临床疗效与治疗依从性的影响[J].国际精神病学杂志,2016,43(1):119-122.
[18]徐儒瑾,万学东,舒燕萍.疏肝解郁胶囊与艾司西酞普兰治疗抑郁症的临床研究[J].时珍国医国药,2013,24(10):2463-2464.
[19]李倩,张玉娟,王丽娜,等.疏肝解郁胶囊联合艾司西酞普兰改善老年躯体疾病焦虑抑郁状态及治疗依从性研究[J].中华中医药学刊,2018,36(4):970-973.
[20]林世泽,连和谈.艾司西酞普兰联合疏肝解郁胶囊对老年抑郁症伴焦虑疗效观察[J].海峡药学,2016,28(9):134-135.
[2]朴轶峰,李镔,李论,等.住院精神障碍患者合并躯体疾病的调查分析[J].中国当代医药,2017,24(26):151-153.
[3]邵海燕,杨洪娟.精神疾病患者合并躯体疾病的诊治策略[J].临床医药文献电子杂志,2017,4(46):8948-8949.
[4]李文科,钟世洪.艾司西酞普兰治疗伴焦虑症状的抑郁症的研究[J].中国社区医师,2018,34(2):11-13.
[5]李丽静.艾司西酞普兰治疗抑郁症的有效性与安全性分析[J].北方药学,2018,15(1):152-153.
[6]王凯丽,闫西鹏,赵颖颖,等.中医治疗焦虑抑郁症简况[J]实用中医内科杂志,2016,30(9):113-116.
[7]郑晓东,李俊,易飞.疏肝解郁胶囊治疗脑卒中后抑郁患者疗效及日常生活活动能力研究[J].中风与神经疾病杂志,2017,34(5):446-448.
[8]中华医学会精神科分会.CCMD-3中国精神障碍分类与诊断标准[M].济南:山东科学技术出版社,2001:118.
[9]中华医学会精神病学分会.中国精神疾病防治指南[M].北京:北京大学医学出版社,2010:26-30.
[10]吴江,贾建平.神经病学[M].3版.北京:人民卫生出版社,2015:521-523.
[11]汪向东.心理卫生评定量表手册(增订版)[M].北京:中国心理卫生杂志社,1999:223-226.
[12]王洪娟,吴忠海.老年抑郁症与共患躯体疾病、社会支持的关系[J].齐齐哈尔医学院学报,2017,38(5):513-514
[13]马春锋.抑郁发作和复发性抑郁障碍合并躯体疾病的临床分析[J].临床医药文献电子杂志,2017,4(90):17 642-17 644.
[14]张俊,林秀洁,黄礼传.艾司西酞普兰与舒肝解郁胶囊治疗脑卒中后抑郁症对照观察[J].海峡药学,2017,29(5):160-162.
[15]徐彩霞,邓文,李美银,等.艾司西酞普兰与氟西汀治疗老年抑郁症的疗效与安全性对比观察[J].临床合理用药杂志,2012,5(12):39-40.
[16]李开凤.中西医结合治疗焦虑抑郁症疗效观察[J].深圳中西医结合杂志,2015,25(21):33-34.
[17]王学红,杨业,官聪,等.疏肝解郁胶囊联合艾司西酞普兰对老年躯体疾病伴发焦虑抑郁患者临床疗效与治疗依从性的影响[J].国际精神病学杂志,2016,43(1):119-122.
[18]徐儒瑾,万学东,舒燕萍.疏肝解郁胶囊与艾司西酞普兰治疗抑郁症的临床研究[J].时珍国医国药,2013,24(10):2463-2464.
[19]李倩,张玉娟,王丽娜,等.疏肝解郁胶囊联合艾司西酞普兰改善老年躯体疾病焦虑抑郁状态及治疗依从性研究[J].中华中医药学刊,2018,36(4):970-973.
[20]林世泽,连和谈.艾司西酞普兰联合疏肝解郁胶囊对老年抑郁症伴焦虑疗效观察[J].海峡药学,2016,28(9):134-135.